norovirus vaccine (bivalent)

A **bivalent norovirus vaccine** refers to more than one distinct investigational vaccine designed to prevent acute gastroenteritis caused by norovirus by inducing immune responses against two major norovirus genogroups, typically GI.1 and GII.4. In the provided context, this term is **non-specific** and most notably maps to two separate products: **HIL-214**, an intramuscular **virus-like particle** vaccine containing GI.1 and GII.4c VP1-derived VLP antigens adjuvanted with aluminum hydroxide and developed by Takeda and HilleVax; and **Vaxart's oral tablet vaccine**, a **recombinant adenoviral vector** vaccine composed of VXA-G1.1-NN and VXA-G2.4-NS, encoding VP1 antigens from GI.1 Norwalk and GII.4 strains with a dsRNA adjuvant in an enteric-coated tablet. These biologic vaccines are intended to generate serum and mucosal immune responses, including neutralizing and histoblood group antigen blocking antibodies targeting the VP1 major capsid protein, and have been studied in Phase 1 and Phase 2 development for prevention of norovirus-induced acute gastroenteritis.

Other names

bivalent norovirus vaccineGI.1/GII.4 norovirus vaccine